WHO

WHO Paediatric ARV dosing dashboard

2022

The WHO have developed a Paediatric ARV dosing dashboard which aims to support health care workers, researchers and policy makers in decisions around ARV dosing for children. It includes a dosing tool to assist in selecting the correct dose for infants, children and adolescents less than 18 years old, background information to support WHO paediatric weight-band dosing recommendations for ARV drugs, and a tool for researchers who want to investigate various ARV dosages and calculate the expected drug exposure in children relative to adult targets after administration of various doses.

Read More

Gap-f launches strategy plan!

2022

On March 1, 2022, the GAP-f network held a virtual event to launch its ambitious three-year strategy, spanning from 2022-2024. Through this event, the network solidified the WHO’s commitment to advancing health outcomes for children globally.

GAP-f’s three-year strategy (2022–2024) builds from the work undertaken to date by the network of leading partners, both individually and collectively, through GAP-f. The initial Phase I strategy focused on HIV, tuberculosis (TB) and hepatitis C products,

Read More

New findings from the ODYSSEY trial confirm superiority of dolutegravir-based ART in younger children – A story by WHO

2021

WHO welcomes new findings presented today at International Pediatric HIV Workshop on the superiority of dolutegravir (DTG)-based regimens in young children.

Children living with HIV continue to be left behind by the global AIDS response. In 2020, only 54% of the 1.7 million children living with HIV received antiretroviral therapy in 2020 compared to 74% among adults living with HIV. Among the focus countries, only 40% of children living with HIV (or 74% of children receiving antiretroviral therapy) achieved viral suppression in 2020.

Read More

Call for comments on the WHO Zika virus Research and Development Roadmap

2021

The WHO is calling on the public to share their comments on the newly drafted Zika virus Research and Development (R&D) Roadmap, a key component of the WHO’s R&D Blueprint which is a global strategy and preparedness plan that allows the activation of R&D activities in advance of and during pandemics. Comments can be submitted by completing this form. The Zika virus R&D roadmap aims to accelerate the development and implementation of effective medical countermeasures for the Zika virus so as to reduce morbidity,

Read More